One other report in 2016 similarly showed that in vivo mAb-mediated blockade of CD49a or CD103 significantly impaired the control of subcutaneous B16-OVA tumors, supporting important roles for these molecules in T cell mediated anti-tumor immunity (109). The gene discussed is ITGA1; the disease is neoplasm.